Aura Biosciences, Inc.

AURA Nasdaq CIK: 0001501796

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation DE
Business Address 80 GUEST STREET, BOSTON, MA, 02135
Mailing Address 80 GUEST STREET, BOSTON, MA, 02135
Phone (617)500-8864
Fiscal Year End 1231
EIN 320271970

Financial Overview

FY2025

$-1.75
EPS

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report April 16, 2026 View on SEC
10-K Annual financial report March 30, 2026 View on SEC
8-K Current report of material events March 30, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report February 17, 2026 View on SEC

Annual Reports

10-K March 30, 2026
  • Lead drug candidate bel-sar showed 80% tumor control in Phase 2 eye cancer trials.
  • 90% of patients in clinical trials maintained their vision, outperforming current standards.
View Analysis

Insider Trading

STRONG SELL 5 insiders 8 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.